BioStem Technologies’ Promising Clinical Study on Venous Leg Ulcers

BioStem Technologies ((BSEM)) announced an update on their ongoing clinical study.

BioStem Technologies is conducting a clinical study titled A Prospective, Multicenter, Randomized, Controlled Trial of Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC. The study aims to evaluate the effectiveness of the human placental allograft BioREtain® Amnion Chorion (BR-AC) in promoting healing in non-healing venous leg ulcers (VLUs) compared to standard care alone. The significance lies in potentially improving treatment outcomes for patients with chronic VLUs.

The intervention being tested is BR-AC, a placental membrane product processed by BioStem Technologies. It is designed to enhance wound healing when applied directly to the wound surface, in conjunction with standard care procedures like debridement and compression therapy.

The study design is interventional, with participants randomly assigned to either the experimental group receiving BR-AC plus standard care or the control group receiving only standard care. The primary purpose is treatment, and the study employs a single-masking model where an independent reviewer assesses wound closure outcomes to minimize bias.

The study began on February 14, 2025, with the last update submitted on June 26, 2025. These dates are crucial for tracking the study’s progress and ensuring transparency in its execution.

This study update could positively impact BioStem Technologies’ stock performance by showcasing potential advancements in wound care treatment. Investors may view this as a promising development, especially if the study results demonstrate significant improvements over existing treatments. Competitors in the wound care industry may need to consider similar innovations to maintain market relevance.

The study is ongoing, and further details can be accessed on the ClinicalTrials portal.